Liquid Biopsy Supports Precision Oncology

Experts highlight clinical value, workflow integration, and real-world impact in lung and breast cancer diagnostics

1

Liquid biopsy comprehensive genomic profiling (CGP) enhances precision oncology by providing earlier insights and faster access to targeted therapies.
2

Liquid biopsy offers a non-invasive alternative to tissue testing, addressing limitations in obtaining sufficient tumor samples for genomic profiling.
3

ctDNA analysis captures tumor heterogeneity and resistance mechanisms, providing a broader view than single tissue biopsies for treatment decisions.
4

Integrating liquid biopsy into lung cancer pathways significantly reduces turnaround times for actionable results and accelerates treatment allocation.
5

In breast cancer, ctDNA testing for ESR1 mutations demonstrates rapid results and the ability to detect low-frequency variants, aiding therapy guidance.

1